Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol vs Combination Therapy for Variceal Bleeding Prophylaxis in HCC
NCT06836778Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of carvedilol in esophageal varices (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients developing variceal bleed at 6 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
carvedilol
03
Conditions
esophageal varices
Beyond the preview
Go deeper on NCT06836778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836778.